Discoidin Domain Receptor Antagonists Pipeline Insight
DelveInsight’s, “Discoidin Domain Receptor Antagonists - Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Discoidin Domain Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discoidin Domain Receptor Antagonists Understanding
Discoidin Domain Receptor Antagonists: Overview
The discoidin domain receptor (DDR) family comprises two distinct members, DDR1 and DDR2, which were initially discovered in the early 1990s and characterized as receptor tyrosine kinases (RTKs) based on the presence of a catalytic kinase domain (KD). Subsequently, collagens were identified as ligands for DDRs, thus establishing the unique characteristic of these receptors among other members of the RTK superfamily. Upon collagen binding, DDRs undergo tyrosine autophosphorylation with distinctive activation kinetics, which elicits genetic and cellular programs that regulate a variety of cell-collagen interactions.
The companies and academics are working to assess challenges and seek opportunities that could influence Discoidin Domain Receptor Antagonists R&D. The therapies under development are focused on novel approaches for Discoidin Domain Receptor Antagonists.
Discoidin Domain Receptor Antagonists Emerging Drugs Chapters
This segment of the Discoidin Domain Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Discoidin Domain Receptor Antagonists Emerging Drugs
Merestinib: Eli Lilly and Company
Merestinib (LY2801653) is an experimental cancer drug in development by Eli Lilly. It is a small molecule inhibitor of MET and several other receptor tyrosine kinases such as MST1R, FLT3, AXL, MERTK, TEK, ROS1, NTRK1/2/3, and DDR1/2.Meristinib is part of a phase II clinical trial for advanced billiary tract cancer.
APL-102 is an oral, small molecule multi-tyrosine kinase inhibitor (MTKI) targeting several key oncogenic drivers. APL-102 inhibits several receptor tyrosine kinases (RTKs), including; Angiogenesis via Vascular Endothelial Growth Factor Receptors (VEGFR); Mitogen-Activated Protein Kinases (MAPK) pathway via B-RAF and C-RAF; and Colony stimulating factor 1 receptor (CSF1R). Shown to inhibit several kinases which are aberrantly activated in cancer cells, including VEGFR, MAP4K5, c-RAF and DDR1. APL-102 has demonstrated broad and potent preclinical anti-tumor activity in patient-derived xenograft models of colon, liver, breast, kidney, esophageal and lung cancers. In China, the company received Investigational New Drug (IND) approval, and is conducting a Phase 1 dose escalation and extension study of APL-102 in subjects with solid tumors as a monotherapy.
Further product details are provided in the report……..
Discoidin Domain Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Discoidin Domain Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Discoidin Domain Receptor Antagonists
There are approx. 4+ key companies which are developing the Discoidin Domain Receptor Antagonists. The companies which have their Discoidin Domain Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase II include, Eli Lilly and Company.
DelveInsight’s report covers around 6+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Discoidin Domain Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Discoidin Domain Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Discoidin Domain Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Discoidin Domain Receptor Antagonists drugs.
Discoidin Domain Receptor Antagonists Report Insights
- Discoidin Domain Receptor Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Discoidin Domain Receptor Antagonists Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Discoidin Domain Receptor Antagonists drugs?
- How many Discoidin Domain Receptor Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Discoidin Domain Receptor Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Discoidin Domain Receptor Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Discoidin Domain Receptor Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?